OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays

Share Article

OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

Through development of this unique class of high quality antibodies in SISCAPA based applications, OriGene will maintain its leadership position as the world’s premiere monoclonal antibody company."

OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

OriGene’s winning of this grant is rooted in its insightful investment in the novel technology of SISCAPA. In early January, 2014, OriGene announced its strategic intent to work with SISCAPA technology, developed by Dr. Leigh Anderson, to solve the multifaceted challenge of developing antibodies to specific peptides generated by the fragmentation of the target protein. Through its on-going collaboration with the Institute for Systems Biology (ISB) and with the assistance of NCI’s Clinical Proteomic Technologies for Cancer (CPTC) group, OriGene has made rapid advancements in its efforts to produce high quality antibodies for use in SISCAPA assays to every human protein.

“Development of high-affinity anti-peptide antibodies to every human protein for use in SISCAPA technology is critical to the advancement of this multiplexed protein assay technology platform” stated Dr. Donghui Ma, Senior Vice President and Head of Antibody Development at OriGene Technology. “OriGene’s ability to effectively apply its unique capabilities to the challenges of high quality monoclonal antibody development and determination of antibody specificity are perfectly suited to enable researchers to ultimately realize the promise of SISCAPA technology. Through development of this unique class of high quality antibodies in SISCAPA based applications, OriGene will maintain its leadership position as the world’s premiere monoclonal antibody company and expand the roster of effective tools available for antibody based research.”

“High quality and specific antibodies are critical to the successful development, as well as long-term adoption of SISCAPA based assays in studying human disease. The opportunity to expand our collaboration and further support this SBIR contract is a fantastic way to better leverage our collective knowledge to usher in the next paradigm of assays to quantitatively assess proteins” commented Dr. Robert Moritz, Professor and Director of Proteomics Research at ISB.

OriGene is one of the industry’s largest suppliers of monoclonal antibodies to the life science research and global IVD communities through the production of its TrueMAB™ and UltraMAB® Antibody product lines. In 2010 OriGene established one of the world’s largest high-throughput monoclonal antibody development and validation facilities at the Company’s WuXi, China location. Through its SDIX LLC subsidiary based in Newark, DE, the company has established its GMP and ISO13485 certified quality management system and expanded capacity for diagnostic antibody manufacturing.

Additional information about OriGene Technologies and its rapidly expanding TrueMAB Antibody product portfolio is available at http://www.origene.com.
*TrueMAB™ Antibodies and UltraMAB® Antibodies are registered trademarks of OriGene Technologies, Inc.

About OriGene Technologies:
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 12,000 purified human proteins produced from mammalian (HEK293) cells, over 50,000 high quality primary antibodies including TrueMAB ™ mouse monoclonal antibodies and polyclonal antibodies made against full-length proteins for the conservation of native epitopes, validated “mono-specific” monoclonal antibodies called UltraMAB® which offer a unique solution to the critical issue of antibody specificity, >140,000 highly validated human tissues, and protein microarray products and services. For more information, visit http://www.origene.com.

About ISB:
The Institute for Systems Biology is a nonprofit biomedical research organization based in Seattle, Washington. It was co-founded in the year 2000 by systems biologist and President of ISB, Prof. Leroy Hood,. ISB was established on the belief that the conventional models for exploring and funding breakthrough science have not caught up with the real potential of what is possible today. ISB serves as the ultimate environment where scientific collaboration stretches across disciplines, where our researchers have the intellectual freedom to challenge the status quo, and where grand visions for breakthroughs in human health inspire a collective drive to achieve the seemingly impossible. Our core values ensure that we always keep our focus on the big ideas that eventually will have the biggest impact on human health. Since 2000, ISB has grown to over 200 staffers, which includes 10 faculty members and laboratory groups. Additional information about ISB is available at http://www.systemsbiology.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mark Watson
OriGene Technologies
301-340-3188 Ext: 235
Email >
Follow us on
Visit website